One method is to hope that the plaintiffs die:
Wall Street now believes Merck’s ultimate Vioxx liability is closer to $5 billion than $25 billion, Lehman Brothers analyst Tony Butler adds. The reasoning – with fewer than 20 lawsuits so far making it to trial, some plaintiffs won’t live long enough to see any money.
